Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.2100 (-2.31%) ($11.2100 - $11.2100) on Fri. Dec. 8, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.41% (three month average) | RSI | 59 | Latest Price | $11.2100(-2.31%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD advances 2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) SPY(79%) TAN(72%) XBI(70%) IBB(69%) XLB(68%) | Factors Impacting FOLD price | FOLD will decline at least -1.705% in a week (0% probabilities). VIXM(-15%) UUP(-14%) URA(-12%) TBT(-3%) BLOK(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.705% (StdDev 3.41%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.18(0.27%) | 10 Day Moving Average | $11.01(1.82%) | 20 Day Moving Average | $10.84(3.41%) | To recent high | -16% | To recent low | 12.5% | Market Cap | $2.895b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |